InvestorsHub Logo

Trustbaby

01/09/19 9:18 AM

#17644 RE: alexander77 #17643

And, like Keytruda, once approved for one type of cancer, it's fairly quick and easy to get approved for another type of cancer.

pijoe

01/09/19 11:07 AM

#17645 RE: alexander77 #17643

I dont think he realizes most of the intelligent people that are talking in serious to the moon idea on price is for a buyout which would create the moon price at this share structure.

If brought to market there will be several rounds of dilution, a partnership, lack of revenue per usual for a while since debt to income ratio will remain high in the negative for a while. It would be several years until the revenue really starts to turn heads. This is also because new revenue will likely spark new trials in other indications for Multikine, bonuses, pay raises commensurate to the new or expected market value etc. They would expand the facility, fill it out, hire new personnel at 75-125k per person plus their benefits etc etc. I could go on and on but this 30 seconds of typing is enough :)

alexander77

01/09/19 11:37 AM

#17647 RE: alexander77 #17643

Just mark the previous post. If P3 is succesfull a buyout will follow for at least $4b.